Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Essential thrombocythemia during treatment of acute myeloid leukemia with JAK2 V617F mutation: A case report of a CARE-compliant article.

Medicine - 1 Jul 2018

Ding Wenwen, Li Danni, Zhuang Chao, Wei Pingping, Mou Wenfeng, Zhang Lei, Liang Hui, Liu Yong

Abstract excerpt

RATIONALE: The JAK2 V617F mutation is frequently found in ET, while it is rare in de novo AML. ET has a low frequency of leukemic transformation. Both secondary AML (sAML) from ET and AML with JAK2 V617F mutation have poor prognoses. Because of the low incidence of JAK2 mutation in acute myeloid leukemia (AML), the clinical features of AML with JAK2 mutation are rarely reported so far, either transformed from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Diagnosis, Differential

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fatal Outcome

Share to Janus Kinase 2

Share to Leukemia, Megakaryoblastic, Acute

Share to Leukemia, Myeloid, Acute

Share to Platelet Count

Share to Thrombocythemia, Essential

Source

Open in PubMed Open full text

Identifiers

PMID: 29979407
DOI: 10.1097/MD.0000000000011331
PMCID: PMC6076173

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Essential thrombocythemia during treatment of acute myeloid leukemia with JAK2 V617F mutation: A case report of a CARE-compliant article.PMID 29979407Read ↗

[Analysis of Essential Thrombocythemia to Acute Myeloid Leukemia].Semantic proximity Read ↗

[Essential thrombocythemia with JAK2 V617F mutation transformed into acute myeloid leukemia without JAK2 V617F mutation:case report and literature review].Semantic proximity Read ↗

New advances in the pathogenesis and therapy of essential thrombocythemia.Semantic proximity Read ↗

[Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].Semantic proximity Read ↗

Evaluation of clinical and laboratory findings with JAK2 V617F mutation as an independent variable in essential thrombocytosis.Semantic proximity Read ↗

[Sequential development of BCR::ABL1-positive chronic myeloid leukemia during treatment of JAK2 V617F-positive essential thrombocythemia].Semantic proximity Read ↗

<i>JAK2</i><sup>V617F</sup> mutation in essential thrombocythaemia: clinical associations and long‐term prognostic relevanceSemantic proximity Read ↗

Acquired JAK-2 V617F Mutational Analysis in Pakistani Patients with Essential Thrombocythemia.Semantic proximity Read ↗

Essential thrombocythemia.Semantic proximity Read ↗

Essential thrombocythemia A retrospective case series.Semantic proximity Read ↗

The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia.Semantic proximity Read ↗

Transformation into acute myeloid leukemia with t(8;21)(q22;q22.1); RUNX1::RUNX1T1 from JAK2-mutated essential thrombocythemia: a case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.